Needham Downgrades Geron (GERN) to Hold
More News related to GERN
- Geron (GERN) Presents Interim Data from Imetelstat at AACR-NCI-EORTC Int. Conference
- Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC
- Geron to Present at LCM Healthcare Conference
- Trading Outlook for StemCells Inc. Issued by InvestorSoup.com
- Geron Corp. (GERN) Reports that hESC-Derived Oligodendrocyte Progenitor Cells Reduced Cervical Spinal Cord Injury
More News related to Downgrades
- Hemispherx (HEB) Shares Breaking Out as $1 Technical Level Holds; Stock Up 23%
- Activision's (ATVI) Call of Duty Amasses $3 Billion in Global Sales
- Casino Stocks Tumble Sharply Amid Dubai Concerns (MGM, LVS, WYNN)
- Dubai Fallout ETF Trades
- Apple (AAPL) Shares to Open Below $200 as Dubai World Debt Weighs on Stocks
Needham & Co. downgrades Geron (Nasdaq: GERN) from Buy to Hold.
Visit our Analyst Ratings page to see all the upgrades/downgrades on shares of Geron.
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
Related Categories
DowngradesStocks Mentioned
-0.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
